ImmunityBio
IBRX
181 hedge funds and large institutions have $256M invested in ImmunityBio in 2024 Q3 according to their latest regulatory filings, with 23 funds opening new positions, 64 increasing their positions, 41 reducing their positions, and 32 closing their positions.
71% more call options, than puts
Call options by funds: $18.7M | Put options by funds: $10.9M
56% more repeat investments, than reductions
Existing positions increased: 64 | Existing positions reduced: 41
0.92% more ownership
Funds ownership: 8.95% → 9.86% (+0.92%)
6% less funds holding
Funds holding: 193 → 181 (-12)
28% less first-time investments, than exits
New positions opened: 23 | Existing positions closed: 32
35% less capital invested
Capital invested by funds: $391M → $256M (-$135M)
100% less funds holding in top 10
Funds holding in top 10: 2 → 0 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$14.2M |
| 2 |
Morgan Stanley
New York
|
+$7.77M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
+$5.14M |
| 4 |
Millennium Management
New York
|
+$4.73M |
| 5 |
State Street
Boston,
Massachusetts
|
+$3.66M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
-$7.5M |
| 2 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$1.59M |
| 3 |
MG
Marex Group
London,
|
-$1.38M |
| 4 |
CAC
Cowen and Company
New York
|
-$1.26M |
| 5 |
National Bank of Canada
Montreal,
Quebec, Canada
|
-$828K |
IBRX Hedge Fund Activity: Q3 2024 in Review
181 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in ImmunityBio (IBRX) for Q3 2024, worth a combined $256M — down 35% from $391M a quarter earlier.
Sellers outnumbered buyers: 32 funds closed out of IBRX and 23 opened new positions — a net loss of 9 holders — while 41 trimmed existing stakes and 64 added.
The largest buyer was Vanguard Group, adding an estimated $14.2M. The largest seller was Jane Street, cutting an estimated $7.5M.
- 181 institutional investors held ImmunityBio (IBRX) as of Q3 2024, down from 193 in Q2 2024.
- Funds reported $256M of ImmunityBio stock for Q3 2024, down 35% quarter-over-quarter.
- 23 funds opened new ImmunityBio positions in Q3 2024 and 32 closed out, a net change of -9 holders.
- The largest ImmunityBio buyer in Q3 2024 was Vanguard Group, an estimated $14.2M added.
- The largest ImmunityBio seller in Q3 2024 was Jane Street, an estimated $7.5M sold.
Based on aggregated 13F filings for Q3 2024.